LeslieLPopplewellMD

Oncology • Duarte, CA

Hematologic Oncology

Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

Join to view full profile

Dr. Popplewell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Popplewell's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111

Fax+1 626-301-8973

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
Temple University HospitalResidency, Internal Medicine, 1992 - 1995
University of Louisville School of MedicineClass of 1992

Certifications & Licensure

GA State Medical License 2023 - 2026
IL State Medical License 2023 - 2026
CA State Medical License 1998 - 2025
AZ State Medical License 2002 - 2017
PA State Medical License 1993 - 1995
American Board of Internal Medicine Hematology

Clinical Trials

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Start of enrollment: 2005 Sep 01
Completed
Phase 2
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2005 Jun 29
Completed
Phase 1, Phase 2
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Start of enrollment: 2009 Jul 01
Completed
Phase 1
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2010 May 01
Terminated
Phase 1
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 19
Active, not recruiting
Phase 1, Phase 2
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2012 Nov 19
Completed
Phase 1
Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator Start of enrollment: 2013 Jun 24
Completed
Phase 2
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma Start of enrollment: 2013 Oct 08
Active, not recruiting
Phase 1
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2014 Jun 19
Active, not recruiting
Phase 1
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Start of enrollment: 2023 Aug 01
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) Start of enrollment: 2020 May 21
Recruiting
Phase 1, Phase 2
Roles: Contact
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma.
Swetha Kambhampati Thiruvengadam, Matthew G Mei, Lu Chen, Sandrine Puverel, Robert Chen
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01
2 citations
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymp...
Alex F Herrera, Jasmine Zain, Kerry J Savage, Tatyana Feldman, Jonathan E Brammer
The Lancet. Haematology. 2024-09-01
Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.
Ibrahim Aldoss, Jianying Zhang, Marjorie Robbins, Joo Song, Monzr M Al Malki
Leukemia & Lymphoma. 2024-08-01

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET
David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood

Abstracts/Posters

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center
Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma
Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...
Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma
Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

KOCO 5’S Zach Rael Donates Stem Cells to Try to Save a Cousin’s LifeJuly 17th, 2020
Implant-Associated Cancers: A Look Beyond Breast Implant-Associated Anaplastic Large Cell LymphomaSeptember 16th, 2019
City of Hope Awarded Lymphoma Specialized Programs of Research Excellence (SPORE) Grant from National Cancer InstituteFebruary 21st, 2019
Join now to see all